more »These are pharmacophorically rich intermediates specifically designed for medicinal chemistry, allowing SAR development and “Hit-to-Lead” optimization.
more »A highly diverse set of over 56,000 hit-like and lead-like molecules widely acknowledged as a critical tool in screening campaigns.
more »14,400 compounds selected to represent the overall diversity of the screening collection.
more »A selection of small compounds (MW<300) taken from the Maybridge collection for use in fragments screening to further accelerate the identification of lead compounds.
more »A convenient and cost-effective service that provides customers with Maybridge’s novel new minimally-substituted reactive intermediates as soon as they are produced.
more »Provides a single point of contact for custom synthesis solutions for both the discovery and early development phases of pharmaceutical R&D – up to kilogram scale in-house, with access to multi-kilogram quantities with trusted partners.
more »Custom libraries for hit exploration and Hit-to-Lead programs, either on an FTE or fee for service basis, drawing on our in-house medicinal chemistry expertise.
